Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Merger or Acquisition (July 2023)
11 slides from Coloplast A/s Class B's merger presentation, Jul 7, 2023
Slide 1: Coloplast to acquire Kerecis
Coloplast to acquire Kerecis Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion July 7, 2023
Slide 2: Disclaimers
Disclaimers This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by the Company and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into any jurisdiction where any such offer or
Slide 3: With the addition of Kerecis, Coloplast aims to accelerate growth to 8-10%
With the addition of Kerecis, Coloplast aims to reach many more patients in need of wound treatment, accelerating growth to 8-10% Long-term financial guidance Mission: To become the world leader in tissue regeneration by sustainably harnessing nature’s own remedies 8-10% more than 30% organic growth
Slide 4: The US-centric biologics segment is the fastest growing advanced wound care segment
The US-centric biologics segment is the fastest growing advanced wound care segment, expected to reach DKK 20+ billion by 2028 The advanced wound care market Size in DKKbn, growth in % The biologics wound care market ILLUSTRATIVE External Devices DKKbn growing low-single digit ~13 EU4+UK US High-sin
Slide 5: With the acquisition, Coloplast adds a long-term growth compounder and enters biologics
With the acquisition, Coloplast adds a long-term growth compounder and enters the attractive biologics segment Kerecis – a sustainable business with a clinically …well-positioned for long-term differentiated technology and a great fit to Coloplast… value creation Growth outlook: Shared mission of ma
Slide 6: Kerecis is transforming wound healing with its clinically differentiated technology platform
Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Revenue distribution by Started in 2009, with headquarters and manufacturing in Iceland wound type DKK 510m Revenue for FY 2021/22 Propriet
Slide 7: The gently processed fish skin supports effective wound healing and sustainable production
The gently processed fish skin supports effective wound healing and has a sustainable and cost-efficient production setup Production and logistics: Product portfolio: Minimal and gentle processing of the fish skin Unique benefits of the technology platform • No known disease transmission from cold w
Slide 8: With a high growth profile and profitability expansion potential, Kerecis supports long-term value creation
With a high growth profile and profitability expansion potential, Kerecis is uniquely positioned to support Coloplast’s long-term value creation Kerecis - financial assumptions Our updated long-term financial guidance will drive continued long-term value creation • FY 2022/23 revenue growth of aroun
Slide 9: Transaction price is up to USD 1.3 billion with closing expected during Q4 2022/23
Transaction price is up to USD 1.3 billion (around DKK 8.9 billion) with closing expected during Q4 2022/23 • Coloplast acquires Kerecis for an enterprise value of up to USD 1.3 billion (around DKK 8.9 billion) Structure and • Total price for 100% of the share capital is USD 1.2 billion (around DKK
Slide 10: Kerecis is a strong fit to Coloplast's investment case
Kerecis is a strong fit to Coloplast’s investment case and a growth asset that will support long-term value creation Coloplast investment case: • Category leadership positions in a long-term growth industry • Strong culture of innovation dedicated to improving patient outcomes through products and s
Slide 11: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding